Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Keros Therapeutics, Inc.KROS · Entity 6242 | Chief Scientific Officer | July 15, 2022 | July 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Keros Therapeutics, Inc.
Report date July 15, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 95,100 |
Ending reported balance
After 2022-07-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-15 · Exercise / conversion · Acquired 46,034 · Balance 141,134 Row 2 · 2022-07-15 · Sale · Disposed 46,034 · Balance 95,100 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2028-03-25 | Direct | 8,755 |
Reported balance
After 2022-07-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-15 · Exercise / conversion · Disposed 46,034 · Balance 8,755 F2: Immediately exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: Immediately exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2021 Filed Dec 15, 2021 16:48 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,915 | $0.30 | $574.50 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-064218 · doc4.xml · derivative · entry 7 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,905 Underlying: Common Stock · 5,300 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4,561 | $59.78 | $272,656.58 |
DisclosureSEC source: 0001209191-21-064218 · doc4.xml · nonDerivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.145 to $60.07 inclusive. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 739 | $58.73 | $43,401.47 |
DisclosureSEC source: 0001209191-21-064218 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,261 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.125 to $59.03 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 5,300 | $0.30 | $1,590.00 |
DisclosureSEC source: 0001209191-21-064218 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,900 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-064218 · doc4.xml · derivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,205 Underlying: Common Stock · 15,900 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 15,900 | $60.00 | $954,000.00 |
DisclosureSEC source: 0001209191-21-064218 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 16:40 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 15,900 | $0.30 | $4,770.00 |
DisclosureSEC source: 0001209191-21-064218 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:06 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,600 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-063210 · doc4.xml · derivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,105 Underlying: Common Stock · 10,600 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:06 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 10,600 | $50.00 | $530,000.00 |
DisclosureSEC source: 0001209191-21-063210 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 04, 2021 Filed Nov 5, 2021 17:06 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 10,600 | $0.30 | $3,180.00 |
DisclosureSEC source: 0001209191-21-063210 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 17:21 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,293 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-052271 · doc4.xml · derivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,293 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 17:21 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 1,293 | $0.30 | $387.90 |
DisclosureSEC source: 0001209191-21-052271 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 18:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-043392 · doc4.xml · derivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,293 Underlying: Common Stock · 6,500 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 18:29 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 6,500 | $0.30 | $1,950.00 |
DisclosureSEC source: 0001209191-21-043392 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-040651 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,705 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 219 | $52.13 | $11,416.47 |
DisclosureSEC source: 0001209191-21-040651 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,907 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.12 to $52.53 inclusive. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 898 | $51.73 | $46,453.54 |
DisclosureSEC source: 0001209191-21-040651 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,126 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.065 to $52.05 inclusive. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,533 | $50.37 | $77,217.21 |
DisclosureSEC source: 0001209191-21-040651 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,024 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 17:02 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-21-040651 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,557 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 13, 2021 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-032358 · doc4.xml · derivative · entry 7 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,793 Underlying: Common Stock · 500 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option vested or shall vest in equal quarterly installments commencing on March 18, 2018, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| May 13, 2021 Filed May 13, 2021 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 6,220 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001209191-21-032358 · doc4.xml · derivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,220 shares Expires 2027-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 13, 2021 Filed May 13, 2021 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 500 | $0.30 | $150.00 |
DisclosureSEC source: 0001209191-21-032358 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2021 Filed May 13, 2021 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 6,220 | $0.11 | $684.20 |
DisclosureSEC source: 0001209191-21-032358 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-032358 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,355 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 2,650 | $50.00 | $132,500.00 |
DisclosureSEC source: 0001209191-21-032358 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,187 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 11, 2021 Filed May 13, 2021 16:36 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-21-032358 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-026666 · doc4.xml · derivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,005 Underlying: Common Stock · 5,300 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 100 | $61.72 | $6,172.00 |
DisclosureSEC source: 0001209191-21-026666 · doc4.xml · nonDerivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,187 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.625 to $61.725 inclusive Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 729 | $61.08 | $44,527.32 |
DisclosureSEC source: 0001209191-21-026666 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,287 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.58 to $61.535 inclusive. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,473 | $59.99 | $208,345.27 |
DisclosureSEC source: 0001209191-21-026666 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,016 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.55 to $60.43 inclusive. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 998 | $59.10 | $58,981.80 |
DisclosureSEC source: 0001209191-21-026666 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,489 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.54 to $59.52 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5). Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 5,300 | $0.30 | $1,590.00 |
DisclosureSEC source: 0001209191-21-026666 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 16:32 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 9,996 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001209191-21-024612 · doc4.xml · derivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,996 shares Expires 2027-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-quarter (1/4th) of the shares subject to the option vested on July 1, 2017, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 16:32 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 9,996 | $0.11 | $1,099.56 |
DisclosureSEC source: 0001209191-21-024612 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-020480 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,305 Underlying: Common Stock · 5,300 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 4 | $65.47 | $261.88 |
DisclosureSEC source: 0001209191-21-020480 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,191 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 3,557 | $64.72 | $230,209.04 |
DisclosureSEC source: 0001209191-21-020480 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,195 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.325 to $65.295 inclusive. Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,739 | $63.99 | $111,278.61 |
DisclosureSEC source: 0001209191-21-020480 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,752 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.31 to $64.30 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Read SEC document |
| March 11, 2021 Filed Mar 15, 2021 16:43 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 5,300 | $0.30 | $1,590.00 |
DisclosureSEC source: 0001209191-21-020480 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 16:54 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 33,200 | $0.00 Strike: $0.11 | $0.00 |
DisclosureSEC source: 0001209191-21-015278 · doc4.xml · derivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,996 Underlying: Common Stock · 33,200 shares Expires 2027-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-quarter (1/4th) of the shares subject to the option vested on July 1, 2017, and one-twelfth (1/12th) of the remaining shares subject to the option vested or shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date Read SEC document |
| February 26, 2021 Filed Mar 1, 2021 16:54 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 33,200 | $0.11 | $3,652.00 |
DisclosureSEC source: 0001209191-21-015278 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,300 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · derivative · entry 8 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,605 Underlying: Common Stock · 5,300 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 14 | $68.05 | $952.70 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 7 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,991 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 262 | $67.05 | $17,567.10 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.69 to $67.635 inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,845 | $65.99 | $121,751.55 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,267 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.355 to $66.24 inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,272 | $64.93 | $82,590.96 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,112 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.345 to $65.34 inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 1,460 | $63.74 | $93,060.40 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,384 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.345 to $64.34 inclusive. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | SaleCommon Stock | 447 | $62.85 | $28,093.95 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,844 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.33 to $63.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 17:47 UTC | Keros Therapeutics, Inc. KROS · Entity 6242 | Exercise / conversionCommon Stock | 5,300 | $0.30 | $1,590.00 |
DisclosureSEC source: 0001209191-21-010880 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.